Pregnancy after breast cancer: a systematic review and meta-analysis
M Lambertini, E Blondeaux, M Bruzzone… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Many patients and physicians remain concerned about the potential detrimental
effects of pregnancy after breast cancer (BC) in terms of reproductive outcomes and …
effects of pregnancy after breast cancer (BC) in terms of reproductive outcomes and …
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis
L Arecco, E Blondeaux, M Bruzzone… - Human …, 2022 - academic.oup.com
STUDY QUESTION Is it safe to perform controlled ovarian stimulation (COS) for fertility
preservation before starting anticancer therapies or ART after treatments in young breast …
preservation before starting anticancer therapies or ART after treatments in young breast …
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes
L Ma, B Yang, J Wu - Cancer Treatment Reviews, 2024 - Elsevier
Breast cancer diagnosed in premenopausal women tends to be more aggressive and the
benefit of ovarian function suppression (OFS), at least in certain groups of patients, is well …
benefit of ovarian function suppression (OFS), at least in certain groups of patients, is well …
How to protect ovarian function before and during chemotherapy?
L Arecco, T Ruelle, V Martelli, A Boutros… - Journal of Clinical …, 2021 - mdpi.com
A significant number of women receive a cancer diagnosis before their age of natural
menopause. Among these patients, the most frequent neoplasms are breast cancer …
menopause. Among these patients, the most frequent neoplasms are breast cancer …
Human adipose-derived stromal cells transplantation prolongs reproductive lifespan on mouse models of mild and severe premature ovarian insufficiency
G Salvatore, M De Felici, S Dolci, C Tudisco… - Stem Cell Research & …, 2021 - Springer
Background Although recent studies have investigated the ability of Mesenchymal Stromal
Cells (MSCs) to alleviate short-term ovarian damage in animal models of chemotherapy …
Cells (MSCs) to alleviate short-term ovarian damage in animal models of chemotherapy …
Female oncofertility: current understandings, therapeutic approaches, controversies, and future perspectives
KCT Vo, K Kawamura - Journal of Clinical Medicine, 2021 - mdpi.com
Recent advances in early detection and oncological therapies have ameliorated the survival
rate of young cancer patients. Yet, ovarian impairment induced by chemotherapy and …
rate of young cancer patients. Yet, ovarian impairment induced by chemotherapy and …
Knowledge, practice, and attitudes of physicians in low-and middle-income countries on fertility and pregnancy-related issues in young women with breast cancer
SZ Khan, L Arecco, C Villarreal-Garza, B Sirohi… - JCO Global …, 2022 - ascopubs.org
PURPOSE Fertility and pregnancy-related issues are highly relevant for young (≤ 40 years)
patients with breast cancer. Limited evidence exists on knowledge, practice, and attitudes of …
patients with breast cancer. Limited evidence exists on knowledge, practice, and attitudes of …
[HTML][HTML] How I perform fertility preservation in breast cancer patients
MG Razeti, S Spinaci, F Spagnolo, C Massarotti… - ESMO open, 2021 - Elsevier
Additional age-related issues should be considered when managing breast cancer in young
women. 1 Among them, the potential consequences of anticancer treatments on ovarian …
women. 1 Among them, the potential consequences of anticancer treatments on ovarian …
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
C Molinelli, F Parisi, MG Razeti, L Arecco… - Expert Review of …, 2021 - Taylor & Francis
Introduction: The prognosis of patients with HER2-positive early breast cancer has radically
improved after the introduction of (neo) adjuvant anti-HER2 targeted therapy. Trastuzumab …
improved after the introduction of (neo) adjuvant anti-HER2 targeted therapy. Trastuzumab …
De novo metastatic breast cancer arising in young women: review of the current evidence
Women with metastatic breast cancer remains a heterogeneous group of patients with
different prognostic outcomes and therapeutic needs. Young women with de novo metastatic …
different prognostic outcomes and therapeutic needs. Young women with de novo metastatic …